Watch UPB. Know when insiders buy.
One email the day a filing lands. Free.
UPB
Upstream Bio, Inc.
5.31
−0.02 −0.38%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
−$28K
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $290.8MP/E —DIV YIELD —FCF YIELD —REV TTM $3.2M +16.0%NET INCOME −$156.5MNET CASH —52W 5.31 – 32.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $773K | −17.5% | — | −$42.4M | −$39.7M | — | -0.73 | −$35.6M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $1M | +82.7% | — | −$43.6M | −$40.6M | — | -0.75 | −$47.9M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | $668K | +9.0% | — | −$46.2M | −$42.5M | — | -0.78 | −$30.6M | $54K | −$30.7M | Mar 26 |
| Q3 2025 · Sep 30 | $683K | +12.5% | — | −$37.8M | −$33.7M | — | -0.63 | −$22.2M | $64K | −$22.3M | Nov 5 |
| Q2 2025 · Jun 30 | $937K | +83.7% | — | −$44.3M | −$40M | — | -0.74 | −$39.2M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | $566K | −11.6% | — | −$32M | −$27.3M | — | -0.51 | −$41.2M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | $613K | +36.2% | — | −$26.3M | −$21.2M | — | 12.57 | −$19.6M | $185K | −$19.8M | Mar 26 |
| Q3 2024 · Sep 30 | $607K | −2.3% | — | −$18.9M | −$16M | — | -6.96 | −$14M | — | — | Nov 5 |
| Q2 2024 · Jun 30 | $510K | — | — | −$17.5M | −$14.7M | — | -6.50 | −$8M | — | — | Nov 5 |
| Q1 2024 · Mar 31 | $640K | — | — | −$15M | −$10.9M | — | -4.68 | −$17.6M | — | — | Nov 5 |
| Q4 2023 · Dec 31derived | $450K | — | — | −$14.3M | −$11.8M | — | -5.05 | −$16.1M | $0 | −$16.1M | Mar 12 |
| Q3 2023 · Sep 30 | $621K | — | — | −$9.4M | −$3.1M | — | -2.11 | — | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.9M | — | −$160.4M | −$143.4M | -5026.0% | -2.66 | −$133.3M | $165K | −$133.4M | — | — |
| FY2024 · to Dec 31 | $2.4M | — | −$77.8M | −$62.8M | -2650.0% | -5.58 | −$59.2M | $511K | −$59.7M | — | — |
| FY2023 · to Dec 31 | $2.4M | — | −$40.1M | −$20.5M | -862.9% | -12.95 | −$37.9M | $144K | −$38.1M | — | — |
Every number comes from Upstream Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.